ArticleJACC. Case reports2025
Successful Transcatheter Pulmonary Valve Replacement Via the Azygous Vein in a Patient With Interrupted Inferior Vena Cava.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2021, the Food and Drug Administration approved the Harmony Transcatheter Pulmonary Valve System (Medtronic) for the treatment of pulmonary valve regurgitation in pediatric and adult populations with a native or surgically repaired right ventricular outflow tract, thus extending transcatheter pulmonary valve replacement to accommodate larger native right ventricular outflow tract anatomies. CASE SUMMARY: We present the case of a 15-year-old female with a history of heterotaxy, transannular patch repair of double outlet right ventricle, bilateral superior vena cava, interrupted inferior vena cava (IVC), who presented with progressive right ventricular dilation and reduced endurance by cardiopulmonary exercise testing. DISCUSSION: The most common way of delivering the Harmony valve is through the femoral venous approach. When the patient's anatomy precludes femoral venous access, such as vascular occlusions or an interrupted IVC, an alternative option is essential. TAKE-HOME MESSAGE: Deployment of the Harmony valve without a DrySeal sheath through the femoral vein to the azygous vein pathway is feasible in patients with interrupted IVC and lack of internal jugular access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.